British pharmaceutical giant GSK, led by CEO Emma Walmsley, finds itself caught in the crossfire of a new transatlantic trade dispute. Despite Walmsley’s presence at a recent state banquet intended to foster goodwill, Donald Trump has threatened a 100% tariff on branded drugs, putting GSK and the entire UK pharmaceutical sector in a perilous position.
The dilemma for GSK is acute. As a major global player, it relies heavily on the US market, which could become virtually inaccessible if the tariff is implemented. The company’s situation is a direct result of the UK’s failure to include pharmaceuticals in a tariff protection deal signed with the US five months ago, an omission that has left the entire sector vulnerable.
The timing is particularly frustrating for UK industry leaders, who had hoped the high-profile state visit for Trump would lead to a more stable and predictable trade relationship. Instead, the charm offensive has been met with a cold dose of economic nationalism, leaving the sector “in limbo” and undermining a previous US promise of “preferential treatment.”
There is a potential escape route, but it comes with its own set of challenges. Analysts believe the tariffs are designed to spare companies that manufacture their products in the United States. This puts pressure on firms like GSK to weigh the costs and benefits of shifting production to the US, a major strategic decision that cannot be made overnight.
As the UK government engages in frantic, last-minute talks with Washington, GSK and its peers can only watch and wait. Their plight illustrates the precarious situation of multinational corporations in an era of rising protectionism, where long-term business strategies can be upended by sudden and politically motivated policy shifts.